The Advisory Committee on Immunization Practices’ (ACIP) voted on February 21 to unanimously recommend HEPLISAV-B™ for use among individuals age 18 years and older to prevent hepatitis B infection (HBV). The Hepatitis B Foundation welcomes the use of the new vaccine, which is expected to increase immunization rates for adults in the United States. HEPLISAV-B™ was approved for use by the FDA on July 28, 2017. It is the first new hepatitis B vaccine in more than 25 years, and the only two dose vaccine for the prevention of infection.

Read more here.

Click to read more on HEPLISAV-B,  clinical trials of Hepsilav-B, the potential impact of Hepsilav-B approval, and Dynavax’s press release following the vote.


©2021 HepFree.NYC. All rights reserved. Site by Lookit®


Log in with your credentials

Forgot your details?